Sandoz Group (D8Y0) Stock Overview
Develops, manufactures, and markets generic and biosimilars worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for D8Y0 from our risk checks.
D8Y0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Sandoz Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 73.00 |
| 52 Week High | CHF 79.50 |
| 52 Week Low | CHF 33.20 |
| Beta | 0.33 |
| 1 Month Change | 10.61% |
| 3 Month Change | 22.69% |
| 1 Year Change | 72.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 178.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| D8Y0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.0% | -6.9% | -4.7% |
| 1Y | 73.0% | 10.2% | 2.3% |
Return vs Industry: D8Y0 exceeded the German Pharmaceuticals industry which returned 18.5% over the past year.
Return vs Market: D8Y0 exceeded the German Market which returned 6.1% over the past year.
Price Volatility
| D8Y0 volatility | |
|---|---|
| D8Y0 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 13.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: D8Y0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine D8Y0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 22,356 | Richard Saynor | www.sandoz.com |
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms.
Sandoz Group AG Fundamentals Summary
| D8Y0 fundamental statistics | |
|---|---|
| Market cap | €31.65b |
| Earnings (TTM) | €785.31m |
| Revenue (TTM) | €9.59b |
Is D8Y0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D8Y0 income statement (TTM) | |
|---|---|
| Revenue | US$11.16b |
| Cost of Revenue | US$5.86b |
| Gross Profit | US$5.30b |
| Other Expenses | US$4.39b |
| Earnings | US$914.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 05, 2026
| Earnings per share (EPS) | 2.11 |
| Gross Margin | 47.50% |
| Net Profit Margin | 8.19% |
| Debt/Equity Ratio | 56.6% |
How did D8Y0 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/04 23:38 |
| End of Day Share Price | 2026/03/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sandoz Group AG is covered by 30 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sidhartha Modi | Barclays |
| Emily Field | Barclays |
| James Gordon | Barclays |